Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that the combination of lenalidomide and SNS01-T, the subject of Senesco’s on-going multiple myeloma clinical study, performs better than either treatment alone in mouse xenograft models of human mantle cell lymphoma. The results will be presented with the Company update during Biotech Showcase 2012 at 10.30 a.m. on Wednesday, January 11, 2012 in Track C at the Parc 55 Wyndham Hotel, 55 Cyril Magnin Street in San Francisco. “It is extremely positive that SNS01-T appears to combine well with lenalidomide in this in vivo model,” said Leslie J. Browne, Ph.D., President and CEO of Senesco. “The results not only provide further support for the use of SNS01-T in multiple myeloma and other B-cell cancers, like mantle cell and large diffuse B-cell lymphoma, but also suggest that combining lenalidomide and SNS01-T could be considerably more efficacious than lenalidomide alone. In addition the results provide guidance in the design of future clinical studies.” The Company recently reported that SNS01-T significantly inhibits the growth of both human mantle cell and diffuse large B-cell lymphomas in mouse xenograft models and that SNS01-T enhances the in vitro potency of certain marketed products when used in combination. Study Results Summary When SCID mice, implanted with an aggressive human mantle cell lymphoma cell line (JVM2), were treated with either 15 mg/kg lenalidomide (5 times weekly by intra-peritoneal injection) or 0.375 mg/kg SNS01-T (twice weekly by intravenous injection) there was a growth delay of 4 days and 14 days, respectively. Mice treated with a combination of both drugs using the same dose levels and dosing regimens exhibited a tumor growth delay of 27 days (p value = 0.0008). The median survival of mice treated with control nanoparticles was 21 days. Mice treated with lenalidomide or SNS01-T had a median survival of 28 days (33 % increase) and 37 days (76 % increase), respectively. Mice treated with the drug combination had a median survival of 52 days, an increase in survival of 148 %. Survival analysis using the Kaplan-Meier method revealed that treatment of mice with the drug combination resulted in statistically significant increases in survival compared to both SNS01-T (p value = 0.002) and lenalidomide (p value = 0.007) alone.